Pilleron S, Soto-Perez-de-Celis E, Vignat J, Ferlay J, Soerjomataram I, Bray F, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601–8.

Article  CAS  PubMed  Google Scholar 

Global Cancer Observatory. Cancer Tomorrow, Globocan 2022 (version 1.1) [Internet]. Lyon (France): International Agency for Research on Cancer; 2024. Available from: https://gco.iarc.who.int. Cited 27 Apr 2025

Health AIo. Welfare. Older Australians. Canberra: AIHW; 2024.

Google Scholar 

Bumanlag IM, Jaoude JA, Rooney MK, Taniguchi CM, Ludmir EB. Exclusion of older adults from cancer clinical trials: review of the literature and future recommendations. Semin Radiat Oncol. 2022;32(2):125–34.

Article  PubMed  PubMed Central  Google Scholar 

An L, Ju W, Zheng R, Zeng H, Zhang S, Chen R, et al. Trends in survival for cancer patients aged 65 years or over from 1995 to 2014 in the United States: a population-based study. Cancer Med. 2023;12(5):6283–93.

Article  CAS  PubMed  Google Scholar 

Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, et al. Global disparities of cancer and its projected burden in 2050. JAMA Netw Open. 2024;7(11):e2443198.

Article  PubMed  PubMed Central  Google Scholar 

Singh H, Kanapuru B, Smith C, Fashoyin-Aje LA, Myers A, Kim G, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the US food and drug administration. J Clin Oncol. 2017;35(15_suppl):10009.

Article  Google Scholar 

Kanapuru B, Singh H, Kwitkowski V, Blumenthal G, Farrell AT, Pazdur R. Older adults in hematologic malignancy trials: representation, barriers to participation and strategies for addressing underrepresentation. Blood Rev. 2020;43:100670.

Article  PubMed  Google Scholar 

Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78–92.

PubMed  Google Scholar 

Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6.

Article  CAS  PubMed  Google Scholar 

Outlaw D, Williams GR. Is the lack of evidence in older adults with cancer compromising safety? Expert Opin Drug Saf. 2020;19(9):1059–61.

Article  PubMed  PubMed Central  Google Scholar 

Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–36.

Article  CAS  PubMed  Google Scholar 

Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014;25(11):2134–46.

Article  CAS  PubMed  Google Scholar 

Diaz FC, Hamparsumian A, Loh KP, Verduzco-Aguirre H, Abdallah M, Williams GR, et al. Geriatric oncology: a 5-year strategic plan. Am Soc Clin Oncol Educ Book. 2024;44(3):e100044.

Article  PubMed  PubMed Central  Google Scholar 

Hamaker M, Lund C, Te Molder M, Soubeyran P, Wildiers H, van Huis L, et al. Geriatric assessment in the management of older patients with cancer—a systematic review (update). J Geriatr Oncol. 2022;13(6):761–77.

Article  CAS  PubMed  Google Scholar 

Parks RM, Holmes HM, Cheung K-L. Current challenges faced by cancer clinical trials in addressing the problem of under-representation of older adults: a narrative review. Oncology and Therapy. 2021;9(1):55–67.

Article  PubMed  PubMed Central  Google Scholar 

Jiang Z, Sun W, Du R, Yang R. A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clin Transl Oncol. 2024;26(9):2116–25.

Article  PubMed  Google Scholar 

Lee SM, Wages NA, Goodman KA, Lockhart AC. Designing dose-finding phase I clinical trials: top 10 questions that should be discussed with your statistician. JCO Precis Oncol. 2021;5:317–24.

Article  PubMed  Google Scholar 

Conaway MR, Petroni GR. The impact of early-phase trial design in the drug development process. Clin Cancer Res. 2019;25(2):819–27.

Article  PubMed  Google Scholar 

Unger JM, Xiao H, Vaidya R, Threlkel SA, Chansky M, Hayes A, et al. The cost of doing business: drug costs in federally sponsored cancer clinical trials. JCO Oncol Pract. 2024;20(10_suppl):10.

Article  Google Scholar 

Zhang SX, Fergusson D, Kimmelman J. Proportion of patients in phase I oncology trials receiving treatments that are ultimately approved. J Natl Cancer Inst. 2020;112(9):886–92.

Article  PubMed  PubMed Central  Google Scholar 

Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352(9):895–904.

Article  CAS  PubMed  Google Scholar 

Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1(3):175–81.

Article  CAS  PubMed  Google Scholar 

Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging trends in modern phase 1 oncology trials. N Engl J Med. 2018;378(23):2242–3.

Article  PubMed  Google Scholar 

Abbasi J. Older patients (still) left out of cancer clinical trials. JAMA. 2019;322(18):1751–3.

Article  PubMed  Google Scholar 

Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–26.

Article  CAS  PubMed  Google Scholar 

Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US food and drug administration based on the surrogate end point of response rate. JAMA Intern Med. 2019;179(7):915–21.

Article  PubMed  PubMed Central  Google Scholar 

Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, et al. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020;126(19):4289–93.

Article  PubMed  Google Scholar 

Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, et al. Referrals to a phase I clinic and trial enrollment in the molecular screening era. Oncologist. 2019;24(7):e518–25.

Article  PubMed  PubMed Central  Google Scholar 

Thomas D. Omico-MoST-PrOSPeCT [Internet]. 2024. Available from: https://gccti.org.au/wp-content/uploads/2024/04/Omico-MoST-and-PrOSPeCT-Thomas.pdf. Cited 6 May 2025.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.

Article  PubMed  Google Scholar 

Moore KN, Martin LP, O’Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112–8.

Article  CAS  PubMed  Google Scholar 

Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162–74.

Article  CAS  PubMed  Google Scholar 

BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, et al. The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: a systematic review. J Geriatr Oncol. 2020;11(3):369–79.

Article  PubMed  PubMed Central